IMMUNEONCO BIOPHARMACEUTICALS (SHANIMMUNEONCO BIOPHARMACEUTICALS (SHANIMMUNEONCO BIOPHARMACEUTICALS (SHAN

IMMUNEONCO BIOPHARMACEUTICALS (SHAN

No trades
See on Supercharts

1541 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. It focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. The company was founded by Dr. Tian Wenzhi in June 2015 and is headquartered in Zhangjiang Science City, China.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
1541 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company